Dear Colleagues and Friends,

On behalf of EAACI, we are delighted to welcome you to Madrid for the 4th International Severe Asthma Forum (ISAF).

Building upon the growing success of the previous ISAF meetings (Gothenburg 2012, Athens 2014, Manchester 2016), the aim of ISAF 2018 is to bring together scientists and clinicians, with a broad range of experience from junior scientists/doctors to key opinion leaders, at a focused meeting dedicated to all aspects of severe asthma.

In recent years, considerable progress has been made in understanding and treating severe asthma, including advances in phenotypic patterns and biomarkers and the availability of novel targeted treatments. These advances have unveiled the heterogeneous basis of asthma, whose nature and definition are being revisited in the light of the new pathophysiological and molecular findings that are continuously emerging.

ISAF is an interactive EAACI Focused Meeting and the programme is designed to facilitate discussions. We hope that this will encourage scientific collaborations and facilitate the translation of emerging discoveries into clinical practice to benefit our patients. We welcome speakers and participants from all over the world to share their knowledge and expertise with us and partake in a truly iterative interdisciplinary dialogue.

Madrid is a modern and vibrant city full of surprises. It has preserved the look and feel of many of its historic neighbourhoods and streets. Madrid is unique with its own rules and culture.

We want to encourage all of you to join the chariot of scientific advances, translational research and personalised medical care. We are confident that ISAF 2018 will be another milestone in this scientific journey.
COMMITTEES

ORGANISING COMMITTEE
Zuzana Diamant, The Netherlands
ISAF 2018 Organising Chair & Asthma Section Chair
Santiago Quirce, Spain
ISAF 2018 Local Secretary
Matteo Bonini, United Kingdom
Asthma Section Secretary

SCIENTIFIC COMMITTEE
Sven Seys, Belgium
Marcin Kurowski, Poland
Enrico Heffler, Italy
Ömer Kalayci, Turkey
Susanne Vijverberg, The Netherlands
Martina Vasakova, Czech Republic
Mariana Couto, Portugal
Leif Bjermer, Sweden
Philippe Gevaert, Belgium
Jürgen Schwarze, United Kingdom
Apostolos Bossios, Sweden

LOCAL SCIENTIFIC AND ORGANISING COMMITTEE
Montserrat Alvaro Lozano, Spain
Oscar Palomares Gracia, Spain
Joaquín Sastre, Spain
Tomás Chivato, Spain
Dario Antolin-Amerigo, Spain
Silvia Sanchez-Garcia, Spain

EAACI PRESIDENT
Ioana Agache, Romania

EAACI VICE-PRESIDENT CONGRESSES
Carsten Schmidt-Weber, Germany

IMPORTANT ADDRESSES

VENUE
Meliá Avenida América
C/ Juan Ignacio Luca de Tena, 36
28027 Madrid, Spain
Tel.: +34 91 423 24 11
E-mail: almudena.velazquez@melia.com

ORGANISERS
EAACI Headquarters
Hagenholzstrasse 111
3rd Floor
8050 Zurich
Switzerland
Tel.: +41 44 205 55 33
E-mail: events@eaaci.org
Website: www.eaaci.org

All information at your fingertips during the congress
• Search – View – Evaluate
• Regular updates to the scientific programme
• Use EAACI Free Internet WiFi to download
• Access to all abstracts
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 - 13:45</td>
<td>Registration</td>
<td>Foyer La Cheminee</td>
<td></td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td>Welcome Address</td>
<td>Zaragoza III &amp; IV</td>
<td>Ioana Agache, Romania</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Zuzana Diamant, The Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Santiago Quirce, Spain</td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td>Severe Asthma: The Immunological Basis of a Heterogeneous Syndrome</td>
<td>Zaragoza III &amp; IV</td>
<td>Chairs: Ioana Agache, Romania</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Oscar Palomares, Spain</td>
</tr>
<tr>
<td>14:00 - 14:45</td>
<td>Innate &amp; Adaptive Pathways in Severe Asthma: Interactions &amp; Pathogenesis</td>
<td></td>
<td>Cezmi Akdis, Switzerland</td>
</tr>
<tr>
<td>14:45 - 15:30</td>
<td>Different Endotypes and Phenotypes drive the Heterogeneity in Severe Asthma</td>
<td></td>
<td>Liam Heaney, United Kingdom</td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td>Coffee Break</td>
<td>Toledo Rooms</td>
<td></td>
</tr>
<tr>
<td>16:00 - 18:00</td>
<td>Diagnostic Controversies &amp; Comorbidities in Severe Asthma (Parallel Session)</td>
<td>Zaragoza III &amp; IV</td>
<td>Chairs: Joaquin Sastre, Spain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Leif Bjermer, Sweden</td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td>Establishing the Diagnosis: when is it (Severe) Asthma?</td>
<td></td>
<td>Ioana Agache, Romania</td>
</tr>
<tr>
<td>16:30 - 17:00</td>
<td>Comorbidities in Severe Asthma from ENT perspective</td>
<td></td>
<td>Philippe Gevaert, Belgium</td>
</tr>
<tr>
<td>17:00 - 17:30</td>
<td>Bronchiectasis in Severe Asthma: a new kid on the block</td>
<td></td>
<td>Eva Polverino, Spain</td>
</tr>
<tr>
<td>17:30 - 18:00</td>
<td>Psychological and Social Aspects in Severe Asthma</td>
<td></td>
<td>Stefano Del Giacco, Italy</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Location</td>
<td>Chairs</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>16:00 - 18:00</td>
<td>NOVEL DIAGNOSTIC &amp; MONITORING TOOLS FOR SEVERE ASTHMA</td>
<td>Zaragoza I &amp; II</td>
<td>Chairs: Omer Kalayci, Turkey</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:15 - 19:15</td>
<td>SATELLITE SYMPOSIUM 1</td>
<td>Zaragoza I &amp; II</td>
<td>(Further information on the page 19)</td>
</tr>
<tr>
<td>19:15 - 20:00</td>
<td>E-POSTER DISCUSSION SESSION I</td>
<td>Toledo Rooms</td>
<td>Chairs: Montserrat Alvaro Lozano, Spain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### THURSDAY, 8 NOVEMBER 2018

**19:15 - 20:00 Station 2**

**Toledo Rooms**

<table>
<thead>
<tr>
<th><strong>EP06 - EP10</strong></th>
<th><strong>EP06</strong></th>
<th><strong>Case Of Asthma Associated With Heart Valves Disease Manifested After Neuraxial Anesthesia</strong></th>
<th><strong>Madona Devidze</strong></th>
<th><strong>Georgia</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EP07</strong></td>
<td><strong>Features of Different Asthma Form in Children</strong></td>
<td>Kateryna Khromykh, Ukraine</td>
<td><strong>EP08</strong></td>
<td><strong>Clinical Symptoms Of Asthma In Children Depending Of The Phenotypical Variant</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kateryna Khromykh, Ukraine</td>
<td>Kateryna Khromykh, Ukraine</td>
<td><strong>EP09</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kateryna Khromykh, Ukraine</td>
<td><strong>EP10</strong></td>
<td><strong>Clinical Features of Asthma in Children with different levels of disease control</strong></td>
</tr>
</tbody>
</table>

**19:15 - 20:00 Station 3**

**Toledo Rooms**

<table>
<thead>
<tr>
<th><strong>EP11 - EP15</strong></th>
<th><strong>EP11</strong></th>
<th><strong>The Impact Of Chronic Epstein-Barr Viral Infection On Regulatory Cells In Patients With Severe Bronchial Asthma And COPD</strong></th>
<th><strong>Anna Konishcheva</strong></th>
<th><strong>Russia</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EP12</strong></td>
<td><strong>Clinical Value Of The Reference Equation And Cut-Off Method For Spirometry Interpretation In Asthmatic Children</strong></td>
<td>Snezhina Lazova, Bulgaria</td>
<td><strong>EP13</strong></td>
<td><strong>The Gene- Oh The Gene Does It Play Some Role In Asthma?</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Snezhina Lazova, Bulgaria</td>
<td><strong>EP14</strong></td>
<td><strong>Quantification Of Alpha One Antitrypsin In Asthmatic Patients In An Allergy Department During Three Years</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Laura Ortega-Martín, Spain</td>
<td><strong>EP15</strong></td>
<td><strong>Tight Junction, Mucin And Inflammasome-Related Molecules Are Differentially Expressed In Eosinophilic, Mixed And Neutrophilic Experimental Asthma In Mice</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Urszula Radzikowska, Switzerland</td>
<td><strong>EP11</strong></td>
<td><strong>- EP15</strong></td>
</tr>
</tbody>
</table>

**Chair:** Sven Seys, Belgium

**Chair:** Victoria del Pozo, Spain
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:15 - 20:00</td>
<td>Toledo Rooms</td>
<td><strong>EP16 - EP20</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Chair:</strong> Irina Bobolea, Spain</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>EP16</strong> - <em>Efficacy And Safety Of Omalizumab In Moderate-Severe Asthma Pediatric Patients: A Case Report</em> Sofia Martina Ramis Fernández, Spain</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>EP17</strong> - <em>Stability Of Serum MicroRNAs As A Diagnostic Biomarker In Asthma</em> Manuel Rial, Spain</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>EP18</strong> - <em>Serum MicroRNAs As Biomarkers Differencing ASThma From COPD, ACO And Healthy Subjects</em> José Rodrigo-Muñoz, Spain</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>EP19</strong> - <em>Peach Tree Pollen Induces Respiratory Symptoms In Exposed Children And Adolescents</em> Maria Luisa Somoza, Spain</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>EP20</strong> - <em>Sensitization To A New Peach Tree Pollen Allergen In Children</em> Maria Luisa Somoza, Spain</td>
</tr>
<tr>
<td>20:45 - 23:00</td>
<td>Royal Academy of Medicine</td>
<td><strong>WELCOME RECEPTION</strong></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>08:00 - 09:00</td>
<td><strong>BREAKFAST SEMINAR - MEET THE EXPERT 1</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Tenerife I</strong></td>
<td><strong>Chair:</strong> Dario Antolin Amerigo, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Severe occupational asthma: Clinical phenotypes and outcomes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Joaquin Sastre, Spain</td>
<td>Santiago Quirce, Spain</td>
</tr>
<tr>
<td>09:00 - 10:30</td>
<td><strong>FROM GENE AND ENVIRONMENTAL FACTORS TO CLINICAL BIOMARKERS IN SEVERE ASTHMA</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Zaragoza III &amp; IV</strong></td>
<td><strong>Chairs:</strong> Santiago Quirce, Spain</td>
<td>Zuzana Diamant, The Netherlands</td>
</tr>
<tr>
<td>09:00 - 09:45</td>
<td>Interaction between genetic and environmental factors in SA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ignacio Davila, Spain</td>
<td></td>
</tr>
<tr>
<td>09:45 - 10:30</td>
<td>Biomarkers (help to define different phenotypes) in Severe Asthma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Leif Bjermer, Sweden</td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Toledo Rooms</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 13:00</td>
<td><strong>NEW INSIGHTS INTO MECHANISMS AND TREATMENT OPTIONS OF NON-TYPE 2 ASTHMA (Parallel Session)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Zaragoza III &amp; IV</strong></td>
<td><strong>Chairs:</strong> Leif Bjermer, Sweden</td>
<td>Zuzana Diamant, The Netherlands</td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>Neutrophilic asthma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sven Seys, Belgium</td>
<td></td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td>Non-inflammatory or pauci-granulocytic asthma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stelios Loukides, Greece</td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td>Non T2-high treatment strategies: there’s light at the end of the tunnel</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Matteo Bonini, Italy</td>
<td></td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td>Role of the Airway Smooth Muscle in Severe Asthma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pascal Chanez, France</td>
<td></td>
</tr>
</tbody>
</table>
### FRIDAY, 9 NOVEMBER 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:00 - 13:00 | **CHILDHOOD SEVERE ASTHMA: FROM EPIDEMIOLOGY TO MANAGEMENT (Parallel Session)**  
Zaragoza I & II  
**Chairs:** Montserrat Alvaro Lozano, Spain | Silvia Sanchez-Garcia, Spain |
| 11:00 - 11:30 | Virus-induced immune pathways in Asthma Development  
Jürgen Schwarze, United Kingdom |
| 11:30 - 12:00 | Preventable factors in difficult Childhood Asthma  
Andrew Bush, United Kingdom |
| 12:00 - 12:30 | Clinical phenotypes in childhood asthma and their impact on management  
Omer Kalayci, Turkey |
| 12:30 - 13:00 | Biologicals in pediatric asthma  
Irina Bobolea, Spain |
| 13:00 - 14:30 | **LUNCH AND E-POSTER DISCUSSION SESSION II**  
Station 1 **EP21 - EP28**  
**Chairs:** Marcin Kurowski, Poland | Jose Olaguibel, Spain |
| 13:00 - 14:30 | **EP21** - Implementation Of Mandatory Electronic Multidisciplinary Pathway Improved Quality And Safety Of Asthma Care In Children: 3 Years’ Experience  
Manal Eldegeir, Saudi Arabia |
| 13:00 - 14:30 | **EP22** - Severe Asthma In Northern Sweden: Prevalence, Costs And Clinical Characteristics  
Helena Backman, Sweden |
| 13:00 - 14:30 | **EP23** - Does Small Airway Predict Bronchial Hyperresponsiveness? An Observational Retrospective Study To Evaluate Small Airways Dysfunction  
Diana Betancor, Spain |
| 13:00 - 14:30 | **EP24** - Real-Life Experience With Mepolizumab In A Severe Asthma Unit  
Irina Bobolea, Spain |
| 13:00 - 14:30 | **EP25** - Exacerbation Rate Reduction With Mepolizumab, Split By Maintenance OCS Use And Eosinophil Levels. A Post-Hoc Analysis Of DREAM And MENSA Studies  
Irina Bobolea, Spain |
| 13:00 - 14:30 | **EP26** - New Approach For Personalized Management Of Asthma: Clustering Analysis In Severe Asthmatic Responders To Omalizumab  
Sheila Cabrejos Perotti, Spain |
<table>
<thead>
<tr>
<th>Time</th>
<th>Station 1</th>
<th>13:00 - 14:30</th>
</tr>
</thead>
</table>
| 13:00 - 14:30 | Station 1 | **EP27** - Severe Asthma Is Associated With Higher Sinus Occupancy And Higher Nasal Polyp Frequency  
José Antonio Castillo, Spain  
**EP28** - CRTH2 MRNA Levels In Peripheral Blood In Adult Patients With Asthma  
Ignacio Dávila, Spain |
<table>
<thead>
<tr>
<th>Time</th>
<th>Station 2</th>
<th>13:00 - 14:30</th>
</tr>
</thead>
</table>
| 13:00 - 14:30 | Station 2 | **EP29 - EP35**  
**Chair:** Apostolos Bossios, Sweden  
**EP29** - Antimicrobial Peptide C-Terminal HCAP18 CATHELICIDIN LL-37 and its content in Children Asthma  
Kateryna Khromykh, Ukraine  
**EP30** - Identification Of Novel Metabolomic Biomarkers Associated With HDM-Allergic Asthma Severity  
Maria Escribese, Spain  
**EP31** - Case Series Evaluation Of Asthmatic Patients Treated With Mepolizumab  
Laura Feijoo Paz, Spain  
**EP32** - High Altitude Climate Treatment Results In Long-Term Improved Asthma Control In Patients With Uncontrolled Severe Asthma  
Karin Fieten, Switzerland  
**EP33** - Patients With Severe Eosinophilic Asthma Treated With Mepolizumab: Results From Our Clinical Practice  
Irene Hernández Martín, Spain  
**EP34** - Population Of Patients With Severe Allergic Asthma In Poland Based On Data From The Drug Programme  
Aleksandra Kucharczyk, Poland  
**EP35** - Misdiagnosed "Severe Asthma" - The Devil Is In The Details  
Snezhina Lazova, Bulgaria |
<table>
<thead>
<tr>
<th>Time</th>
<th>Station 3</th>
<th>13:00 - 14:30</th>
</tr>
</thead>
</table>
| 13:00 - 14:30 | Station 3 | **EP36 - EP42**  
**Chair:** Moisés Antonio Calderón, United Kingdom  
**EP36** - Severe Asthma Phenotypes  
Mariana Lobato, Portugal  
**EP37** - Effectiveness Of Bronchial Thermoplasty (BT) In Patients With Uncontrolled Asthma  
Hanne Madsen, Denmark |
### Station 3
#### Toledo Rooms

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13:00 - 14:30| **EP38** - Asthma Exacerbations In The Paediatric Emergency Department: Relationship With Environmental Factors  
M. Andreína Marques-Mejías, Spain  
**EP39** - Staphylococcal Enterotoxin B And Asthma: Impact On Severity And Asthma Exacerbations  
M. Andreína Marques-Mejías, Spain  
**EP40** - Case Series Of Patients Treated With Reslizumab In A Dedicated Severe Asthma Unit  
Beatriz Moya Camacho, Spain  
**EP41** - Efficacy And Safety Of Reslizumab In Severe Asthma Patients With Inadequate Response To Omalizumab: A Multicentre, Open-Label, Pilot Study  
Luis Pérez De Llano, Spain  
**EP42** - Exposure To House Dust Mite Augments Inflammasome Activation During Rhinovirus Infection In Asthmatic Bronchial Epithelium  
Urszula Radzikowska, Switzerland |

### Station 4
#### Toledo Rooms

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13:00 - 14:30| **EP43** - Efficacy Of Omalizumab To Achieve Asthma And Nasal Polyps Control After Aspirin Desensitization Failure: A Case Report  
Marta Sánchez-Jareño, Spain  
**EP44** - OCS Use In Portuguese Respiratory Patients – Data From The National Prescription Database  
Ana Sá-Sousa, Portugal  
**EP45** - Phenotypes Of Severe Asthma In Clinical Practice  
Tomas Slisz, Czech Republic  
**EP46** - Assessment Of Omalizumab Treatment By Blood Eosinophil Count In Paediatric Patients With Severe Allergic Asthma From The Retrospective, Real-Life STELLAIR Study  
Céline Thonnelier, France  
**EP47** - Real World OCS Use In Asthma In The Netherlands  
Luciën Van Der Vlugt, The Netherlands  
**EP49** - Severe Occupational Asthma: Insights From A Multicenter European Cohort  
Olivier Vandenplas, Belgium |

### SATELLITE SYMPOSIUM 2
#### Zaragoza I & II

(Further information on the page 19)
## FRIDAY, 9 NOVEMBER 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 16:00</td>
<td><strong>PRO/CON SESSION</strong></td>
</tr>
<tr>
<td>Zaragoza III &amp; IV</td>
<td><strong>DEBATE 1</strong>&lt;br&gt;Do we need more Biologicals?&lt;br&gt;<strong>Chair:</strong> Joaquin Sastre, Spain&lt;br&gt;<strong>Pro:</strong> Ioana Agache, Romania&lt;br&gt;<strong>Con:</strong> Leif Bjermer, Sweden</td>
</tr>
<tr>
<td>14:30 - 15:15</td>
<td><strong>DEBATE 2</strong>&lt;br&gt;eHealth is useful in treatment of SA&lt;br&gt;<strong>Chair:</strong> Sven Seys, Belgium&lt;br&gt;<strong>Pro:</strong> Dario Antolin, Spain&lt;br&gt;<strong>Con:</strong> Silvia Sanchez-Garcia, Spain</td>
</tr>
<tr>
<td>15:15 - 16:00</td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td><strong>COFFEE BREAK</strong></td>
</tr>
<tr>
<td>Toledo Rooms</td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:50</td>
<td><strong>EAACI AIT ASTHMA GUIDELINES LAUNCHING</strong>&lt;br&gt;Marek Jutel, Poland</td>
</tr>
<tr>
<td>16:50 - 17:50</td>
<td><strong>ORAL ABSTRACT PRESENTATION</strong>&lt;br&gt;<strong>001 - 004</strong>&lt;br&gt;<strong>Chairs:</strong> Dario Antolin Amerigo, Spain</td>
</tr>
<tr>
<td>Zaragoza III &amp; IV</td>
<td><strong>001</strong>&lt;br&gt;A Spanish Study On Unmet Clinical Needs In Patients With Uncontrolled Severe Asthma&lt;br&gt;Luis Alejandro Pérez De Llano, Spain</td>
</tr>
<tr>
<td>16:50 - 17:05</td>
<td></td>
</tr>
<tr>
<td>17:05 - 17:20</td>
<td><strong>002</strong>&lt;br&gt;Exosomes From Asthmatic Eosinophils Impact On Remodelling Of Lung Structure&lt;br&gt;Beatriz Sastre, Spain</td>
</tr>
<tr>
<td>17:20 - 17:35</td>
<td><strong>003</strong>&lt;br&gt;Definition Of Discriminatory Biomarkers Of Nonallergic And Allergic Asthma And Their Severity And The Role Of Methylation In Their Regulation&lt;br&gt;Selene Baos, Spain</td>
</tr>
<tr>
<td>17:35 - 17:50</td>
<td><strong>004</strong>&lt;br&gt;Human Volatilome Analysis To Identify Individuals With Asthma In Clinical Settings&lt;br&gt;Mariana Valente Farraia, Portugal</td>
</tr>
<tr>
<td>18:00 - 19:00</td>
<td><strong>SATELLITE SYMPOSIUM 3</strong>&lt;br&gt;(Further information on the page 19)</td>
</tr>
</tbody>
</table>
### SATURDAY, 10 NOVEMBER 2018

#### 08:00 - 09:00

**BREAKFAST SEMINAR - MEET THE EXPERT 3**  
**Chair:** Jürgen Schwarze, United Kingdom  
*Algorithms matching the right Biological with the right Patient*  
Oscar Palomares, Spain | Parameswaran Nair, Canada

**Tenerife I**

#### 09:00 - 10:30

**TARGETED TREATMENT OF SEVERE ASTHMA: PRECISION MEDICINE IN CLINICAL PRACTICE**  
**Chairs:** Ioana Agache, Romania | Zuzana Diamant, The Netherlands

**Zaragoza III & IV**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 09:45</td>
<td>Update on Treatable Traits in Severe Asthma</td>
<td>Charlotte Suppli Ulrik, Denmark</td>
</tr>
<tr>
<td>09:45 - 10:30</td>
<td>Emerging targeted therapies for Severe Asthma</td>
<td>Parameswaran Nair, Canada</td>
</tr>
</tbody>
</table>

#### 10:30 - 11:00

**COFFEE BREAK**  
*Toledo Rooms*

#### 11:00 - 13:00

**WORKSHOP 1 (Parallel Session)**

**Zaragoza III & IV**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 11:30</td>
<td>Effect of Exercise on Asthma and Asthma Control</td>
<td>Marcin Kurowski, Poland</td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td>Severe Asthma and Metabolic Syndrome</td>
<td>Apostolos Bossios, Sweden</td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td>Chlorine by-products: a problem for swimming pool workers and competition swimmers</td>
<td>Mariana Couto, Portugal</td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td>Rehabilitation and education in severe asthma; a forgotten option?</td>
<td>Antonio Spanevello, Italy</td>
</tr>
</tbody>
</table>
### WORKSHOP 2 (Parallel Session)

**Consequences of Corticosteroid Treatment in Severe Asthma**

**Chairs:** Santiago Quirce, Spain | Tomas Chivato, Spain

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 11:30</td>
<td>Inhalation technique: effect of know-how on adherence and asthma control</td>
</tr>
<tr>
<td></td>
<td>Paul Hagedoorn, The Netherlands</td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td>Overview of Corticosteroid-related side effects</td>
</tr>
<tr>
<td></td>
<td>Omar Usmani, United Kingdom</td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td>Pharmacoeconomic analysis of ICS-shadow side effects and costs</td>
</tr>
<tr>
<td></td>
<td>Enrico Heffler, Italy</td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td>Strategies to reduce corticosteroids impact on severe asthma</td>
</tr>
<tr>
<td></td>
<td>Martina Vasakova, Czech Republic</td>
</tr>
</tbody>
</table>

### CLOSING AND PRIZE GIVING CEREMONY

**CLOSING AND PRIZE GIVING CEREMONY**

**Joaquin Sastre, Spain**
SAM 2019
4 – 6 April 2019
Munich, Germany
Skin Allergy Meeting

www.eaaci.org/sam2019
SPONSORS AND EXHIBITORS

This section contains information that is promotional in nature, distinct from the scientific/educational content.
Relevant outcomes in allergic asthma

Friday the 9th of November 2018 at 18.00-19.00
The Zaragoza I & II, Meliá Avenida América

Chair: Eike Wüstenberg

Early identification of asthma deterioration for modifying or preventing severe exacerbations.
A clinical trial perspective.
Göran Eriksson, Sweden

Can we influence the natural course of asthma in routine care?
Eike Wüstenberg, Germany
SATELLITE SYMPOSIA

THURSDAY, 8 NOVEMBER 2018

18:15-19:15  SATELLITE SYMPOSIUM
SANOFI-GENZYME AND REGENERON
Type 2 Inflammation in Severe Asthma: Clinical and Therapeutic Implications

CHAIR: Santiago Quirce, Spain

Welcome and Introductions
Santiago Quirce, Spain

Defining Severe Asthma
Zuzana Diamant, The Netherlands

Type 2 Asthma: What Is it and What Mediators Drive It?
Santiago Quirce, Spain

Interactive Session: Identifying Type 2 Asthma in Clinical Practice
G. Walter Canonica, Italy

Closing Remarks and Panel Q&A
Santiago Quirce, Spain

FRIDAY, 9 NOVEMBER 2018

13:15 - 14:15  SATELLITE SYMPOSIUM NOVARTIS
New approaches in severe allergic asthma

CHAIR: Ignacio Dávila, Spain

Defining the severe allergic asthma patient candidate to biologics
Santiago Quirce, Spain

Component resolved diagnosis in severe allergic asthma
Olga Luengo, Spain

18:00 - 19:00  SATELLITE SYMPOSIUM ALK
Relevant outcomes in allergic asthma

CHAIR: Eike Wüstenberg, Germany

Early identification of asthma deterioration for modifying or preventing severe exacerbations. A clinical trial perspective
Göran Eriksson, Sweden

Can we influence the natural course of asthma in routine care?
Eike Wüstenberg, Germany
Sanofi Genzyme and Regeneron
Web: www.understandingtype2asthma.com
Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients’ needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.

GSK
Web: www.gsk.com
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GSK has led the way in developing innovative medicines to advance the management of asthma and COPD for nearly 50 years. Over the last five years we have launched six innovative medicines responding to continued unmet patient need, despite existing therapies. This is an industry leading portfolio in breadth, depth and innovation, developed to reach the right patients, with the right treatment.

SEAIC - Spanish Society of Allergology and Clinical Immunology
Web: www.seaic.org
Founded in 1948, the Spanish Society of Allergology and Clinical Immunology (SEAIC) is one of the oldest allergy societies in the world, currently with 1,460 active members (633 of the members in EAACI). There are 19 committees and commissions in our society and most of the affiliates attend adults and children. Some of our resources are: Periodic publications of positions paper (the last one: Vidal C, Antolín D, Rea, no M, Valero A, Sastre J), Safety and Quality Recommendations in Allergy Medicine (Spanish acronym, RESCAL) J Invest Allergol Clin Immunol 2018; 28 (Suppl. 1):1-39, a textbook of Allergy, 2nd edition 2015 (1700 pages), and a journal: J Invest Allergol Clin Immunol, impact factor 3.45.
ISAF 2018 EXHIBITORS
Novartis
Thermo Fisher Scientific

EAACI FOUNDER SPONSORS
EAACI gratefully acknowledges the support of its Founder Sponsors

PLATINUM LEVEL
Aimmune Therapeutics
ALK
Mylan
Novartis

GOLD LEVEL
Allergopharma
AstraZeneca
Allergy Therapeutics
HAL Allergy
Stallergenes Greer
Thermo Fisher Scientific

SILVER LEVEL
Leti
Uriach

EAACI thanks its sponsors for supporting its Green Meetings initiative
A limited number of travel grants are offered to EAACI Junior Members who are the presenting authors of an accepted abstract. Those who are awarded a travel grant will receive travel costs refunded up to EUR 250 and will be reimbursed after the meeting.

1. Rodrigo Jiménez-Saiz, Canada
2. Luciën Van Der Vlugt, The Netherlands
3. Mariana Valente Farraia, Portugal
4. Lynn S. Greissel, Germany
5. Tomas Slisz, Czech Republic
6. Kateryna Khromykh, Ukraine
7. Snezhina Lazova, Bulgaria
8. Urszula Radzikowska, Switzerland
9. Ana Sá-Sousa, Portugal
GENERAL INFORMATION

ACCREDITATION – CME CREDITS
The ISAF 2018, International Severe Asthma Forum, Madrid, Spain, 08/11/2018-10/11/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 14 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

INTERNET
Free WIFI will be offered in all meeting rooms throughout the duration of the event.
Network: Melia_Hotel
Password: -

MEDIA AND PRESS
Registered journalists have access to all scientific sessions. Please contact EAACI HQ to arrange interviews with clinicians and researchers who are presenting their work at ISAF 2018.

Contact details
EAACI Communications Team
EAACI Headquarters
Hagenholzstrasse 111
3rd Floor
8050 Zurich
Switzerland
Email: communications@eaaci.org

MOBILE PHONE & PHOTOGRAPHY POLICY
Please respect the meeting policy and switch off your mobile phone in all session rooms. Please also note that photography and/or video recording in session rooms is strictly forbidden.

NAME BADGES
Registration badges will be used during the meeting. For identification purposes and admission to session halls, participants are requested to wear their badges at all times. If you lose your badge, a new one can be purchased at a cost of EUR 20 from the Registration Desk.

REGISTRATION DESK (FOYER LA CHEMINÉE)
The Registration Desk is located at the Ground Floor in front of the Lobby of the Cheminée Restaurant.
The opening hours are:
Thursday, 8 November 12:00 – 18:00
Friday, 9 November 07:30 – 18:00
Saturday, 10 November 07:30 – 14:00

EXHIBITION
The exhibition of the meeting will be held in the Toledo Room II. The opening hours of the exhibition are as follows:
Thursday, 8 November 12:00 - 20:00
Friday, 9 November 10:00 - 18:00
Saturday, 10 November 10:00 - 13:30
LANGUAGE
The official language of the meeting is English.

FILM, PHOTO AND VIDEO RECORDINGS
EAACI wants to create a comprehensive overview of the meeting interactions and events that may be of promotional interest to the academy. Accordingly, please be advised that you may be filmed or photographed at any time (in the session halls, poster areas, etc.).

INSURANCE/DISCLAIMER
EAACI will not be held liable for personal injuries or for loss of or damage to property incurred by participants at the ISAF 2018. Participants are encouraged to purchase insurance to cover loss incurred in the event of cancellation, medical expenses or damage to or loss of personal effects when traveling outside of their own countries. EAACI cannot be held liable for any hindrance or disruption of the event, proceedings arising from natural, political, social or economic events or other unforeseen incidents beyond its control. Registration of a participant implies acceptance of this condition. The materials presented at this continuing medical education activity are made available for educational purposes only.

ENVIRONMENTAL POLICY
EAACI is committed to the reducing of the environmental impact of its meetings. Reduce – Reuse – Recycle
6th Pediatric Allergy and Asthma Meeting

PAAM 2019
17 – 19 October 2019
Florence, Italy

www.eaaci.org/paam2019
EAACI RESEARCH AND CLINICAL FELLOWSHIPS 2019

EAACI Fellowships support EAACI Junior Members who wish to spend time in a research or clinical center in another country with up to 20,000 EUR, for a 3 – 12 months period.

For more information please visit www.eaaci.org
European Academy of Allergy and Clinical Immunology
1 – 5 June 2019
Lisbon, Portugal

EAACI Congress 2019
Mapping the new world of allergy

www.eaaci.org #eaaci2019